

**REMARKS**

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

The rejection of claims 51-59, 66-72, 76-78, 84, 85, and 90-92 under 35 U.S.C. § 112 (second paragraph) for indefiniteness is respectfully traversed in view of the above amendments.

The rejection of claim 51-55, 60-64, 66-72, 76-78, 84, 85, and 90-92 under 35 U.S.C. § 112 (first paragraph) for failure to satisfy the written description requirement is respectfully traversed in view of the above amendments. The definition of  $R^4$  has now been amended to cover  $-OC(O)R^{13}$ . The original definition of Formula ID contemplated this substituent of  $R^4$ , and generic support for it in the overall structure of the claimed invention is found in the original definitions of  $R^4$  and  $R^{11}$  which could be  $-OR^{11}$  and  $-C(O)R^{13}$ , respectively. See original claim 1. The definition of  $R^4$  generally has now been narrowed from  $-OR^{11}$  to  $-OC(O)R^{13}$  which is thus fully supported by the original disclosure.

The rejection of claims 51-55, 60-64, 66-73, 76-78, 84, 85, and 90-92 under 35 U.S.C. § 112 (second paragraph) is respectfully traversed in view of the above amendments.

The rejection of claims 51-55, 60, 63, 66, and 84-85 under 35 U.S.C. § 102(b) as anticipated by U.S. Patent No. 4,340,600 to Brenner et al. ("Brenner") is respectfully traversed.

Brenner discloses 4-phenyl-1,2,3,4-tetrahydroisoquinolines and their use in renal dilating methods. However, as to the pending claims, Brenner fails to teach the limitation "wherein if  $R^3$  is  $-S(O)_nR^{12}$ , n cannot be 0, and wherein if  $R^3$  is  $-OR^{11}$ ,  $R^{11}$  cannot be hydrogen". In addition, the specific substituents required by the separately claimed classes of compounds IA-F are not taught by Brenner. Since Brenner fails to teach or suggest compounds satisfying these limitations, it cannot anticipate the claimed invention. Accordingly, the rejection under 35 U.S.C. § 102 should be withdrawn.

In view of all of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: January 21, 2005



Michael L. Goldman  
Registration No. 30,727

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1304  
Facsimile: (585) 263-1600

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

☒ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) \_\_\_\_\_

1/21/05  
Date

  
Signature

Wendy L. Barry  
Type or Print Name